A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia	Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy	Active, not recruiting	Phase 2	2024-12-30		NCT06199089

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Henan Cancer Hospital	147
Institute of Hematology & Blood Diseases Hospital, China	285
North China University of Science and Technology	7
The Second Affiliated Hospital of Kunming Medical University	33
Tianjin Medical University Second Hospital	50
Tianjin People's Hospital	12

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chinese Academy of Medical Science and Blood Disease Hospital	Tianjin	China	15